Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Heartseed, Inc. ( (JP:219A) ) has shared an announcement.
Heartseed Inc. announced the termination of its partnership with Novo Nordisk A/S, which decided to concentrate on its core business areas. As a result, Heartseed regains worldwide rights to its therapeutic programs HS-001 and HS-005 for severe heart failure. The company maintains its earnings forecast for 2025 and reports no safety or efficacy concerns for HS-001, with HS-005 clinical preparations progressing as planned.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3290.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
More about Heartseed, Inc.
Heartseed Inc. operates in the biotechnology industry, focusing on developing therapeutic programs using allogeneic iPS cell-derived cardiomyocytes. The company is involved in creating treatments for severe heart failure, with a market focus on innovative cardiac therapies.
Average Trading Volume: 861,001
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen71.95B
See more insights into 219A stock on TipRanks’ Stock Analysis page.